Illumina, Inc. $ILMN Shares Sold by Biondo Investment Advisors LLC

Biondo Investment Advisors LLC lowered its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 79.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,551 shares of the life sciences company’s stock after selling 54,615 shares during the period. Biondo Investment Advisors LLC’s holdings in Illumina were worth $1,154,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Rakuten Securities Inc. boosted its stake in Illumina by 290.3% in the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company’s stock valued at $29,000 after acquiring an additional 270 shares in the last quarter. Center for Financial Planning Inc. acquired a new position in Illumina in the first quarter valued at $33,000. Fourth Dimension Wealth LLC purchased a new position in Illumina during the fourth quarter worth about $40,000. PFS Partners LLC raised its holdings in Illumina by 400.0% during the first quarter. PFS Partners LLC now owns 500 shares of the life sciences company’s stock worth $40,000 after purchasing an additional 400 shares in the last quarter. Finally, Golden State Wealth Management LLC raised its holdings in Illumina by 123.2% during the first quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company’s stock worth $42,000 after purchasing an additional 292 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of ILMN stock opened at $101.80 on Friday. The company’s fifty day simple moving average is $98.18 and its 200-day simple moving average is $89.13. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The company has a market cap of $15.65 billion, a PE ratio of 12.89, a P/E/G ratio of 2.23 and a beta of 1.37.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.17. The business had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business’s revenue for the quarter was down 4.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, equities research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Upgrades and Downgrades

ILMN has been the subject of several analyst reports. Canaccord Genuity Group increased their target price on shares of Illumina from $99.00 to $105.00 and gave the company a “hold” rating in a report on Friday, August 1st. Robert W. Baird increased their price target on shares of Illumina from $84.00 to $105.00 and gave the company a “neutral” rating in a research report on Monday, July 28th. Evercore ISI increased their price target on shares of Illumina from $116.00 to $128.00 and gave the company an “outperform” rating in a research report on Tuesday, July 8th. Daiwa America lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 12th. Finally, Wall Street Zen lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Seven investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $124.58.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.